Ihor Vynnychenko

21.4k total citations · 7 hit papers
57 papers, 7.0k citations indexed

About

Ihor Vynnychenko is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ihor Vynnychenko has authored 57 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 43 papers in Oncology, 39 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Ihor Vynnychenko's work include Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Gastric Cancer Management and Outcomes (13 papers). Ihor Vynnychenko is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Cancer Immunotherapy and Biomarkers (14 papers) and Gastric Cancer Management and Outcomes (13 papers). Ihor Vynnychenko collaborates with scholars based in Ukraine, United States and Germany. Ihor Vynnychenko's co-authors include Ricard Mesı́a, Didier Cupissol, Carsten Bokemeyer, Frédéric Peyrade, Fernando Rivera, Nadia Amellal, Jan B. Vermorken, Éva Remenár, Armin Schueler and Andrzej Kawecki and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Ihor Vynnychenko

55 papers receiving 6.9k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer

2008 2.6k citations Jan B. Vermorken, Ricard Mesı́a et al. New England Journal of Medicine profile →
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

2009 1.0k citations Robert Pirker, Jose R. Pereira et al. The Lancet profile →
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial

2012 592 citations Mark A. Socinski, Igor Bondarenko et al. Journal of Clinical Oncology profile →
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

2020 498 citations Bohuslav Melichar, Ihor Vynnychenko et al. The Lancet Oncology profile →
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial

2010 425 citations Jaffer A. Ajani, W. Rodriguez et al. Journal of Clinical Oncology profile →
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

2020 405 citations Robert M. Jotte, Federico Cappuzzo et al. Journal of Thoracic Oncology profile →
FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma

2021 244 citations Uğur Şahin, Ö. Türeci et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ihor Vynnychenko Ukraine	21	4.6k	4.3k	1.4k	1.4k	1.4k	57	7.0k
Federica Perrone Italy	50	3.6k 0.8×	2.7k 0.6×	2.1k 1.5×	1.0k 0.7×	2.0k 1.4×	235	7.9k
P. Koralewski Poland	23	4.5k 1.0×	3.5k 0.8×	2.1k 1.5×	478 0.3×	926 0.7×	58	7.1k
Ranee Mehra United States	38	4.1k 0.9×	2.3k 0.5×	1.5k 1.0×	1.7k 1.2×	1.4k 1.0×	194	6.5k
Nadia Amellal France	20	5.3k 1.2×	4.0k 0.9×	2.1k 1.5×	4.2k 3.0×	2.4k 1.7×	60	9.0k
Kelly S. Oliner United States	28	4.6k 1.0×	2.6k 0.6×	1.3k 0.9×	439 0.3×	1.0k 0.7×	68	6.4k
Li Zhang China	39	3.6k 0.8×	2.8k 0.6×	1.4k 1.0×	859 0.6×	930 0.7×	255	6.0k
Mark Kozloff United States	36	3.2k 0.7×	1.7k 0.4×	1.3k 0.9×	540 0.4×	612 0.4×	125	4.7k
Ricardo Hitt Spain	28	4.0k 0.9×	2.9k 0.7×	1.5k 1.0×	3.5k 2.5×	2.0k 1.4×	69	6.7k
Jong‐Mu Sun South Korea	44	4.8k 1.0×	4.4k 1.0×	1.5k 1.0×	190 0.1×	1.2k 0.9×	234	7.1k
F. Cognetti Italy	27	2.3k 0.5×	1.3k 0.3×	933 0.7×	2.2k 1.6×	1.9k 1.4×	129	4.8k

Countries citing papers authored by Ihor Vynnychenko

Since Specialization

Citations

This map shows the geographic impact of Ihor Vynnychenko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ihor Vynnychenko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ihor Vynnychenko more than expected).

Fields of papers citing papers by Ihor Vynnychenko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ihor Vynnychenko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ihor Vynnychenko. The network helps show where Ihor Vynnychenko may publish in the future.

Co-authorship network of co-authors of Ihor Vynnychenko

This figure shows the co-authorship network connecting the top 25 collaborators of Ihor Vynnychenko. A scholar is included among the top collaborators of Ihor Vynnychenko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ihor Vynnychenko. Ihor Vynnychenko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wakelee, Heather A., Nasser K. Altorki, Caicun Zhou, et al.. (2024). IMpower010: Final disease-free survival (DFS) and second overall survival (OS) interim results after ≥5 years of follow up of a phase III study of adjuvant atezolizumab vs best supportive care in resected stage IB-IIIA non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(17_suppl). LBA8035–LBA8035. 6 indexed citations

Reinmuth, Niels, Óscar Juan, Dariusz M. Kowalski, et al.. (2024). Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study. Clinical Cancer Research. 30(18). 4055–4067. 5 indexed citations

Ren, Shengxiang, Jifeng Feng, Shenglin Ma, et al.. (2023). KEYNOTE‐033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD‐L1‐positive, advanced NSCLC. International Journal of Cancer. 153(3). 623–634. 12 indexed citations

Felip, Enriqueta, Chi Zhou, Ihor Vynnychenko, et al.. (2022). 80O Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: Sub-analysis from the pivotal phase III IMpower010 study. Annals of Oncology. 33. S71–S71. 10 indexed citations

Vynnychenko, Ihor, et al.. (2022). Toluidine blue for the detection of sentinel lymph nodes in patients with thyroid cancer. Współczesna Onkologia. 26(4). 259–267. 3 indexed citations

Rugo, Hope S., Eduardo J. Pennella, Jay Herson, et al.. (2021). Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial. The Breast. 58. 18–26. 4 indexed citations

Zhou, C.Z., J. Feng, Shenglin Ma, et al.. (2020). 1262P Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033. Annals of Oncology. 31. S816–S816. 6 indexed citations

Jotte, Robert M., Federico Cappuzzo, Ihor Vynnychenko, et al.. (2020). Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. Journal of Thoracic Oncology. 15(8). 1351–1360. 405 indexed citations breakdown →

Jotte, Robert M., Federico Cappuzzo, Ihor Vynnychenko, et al.. (2019). OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC. Journal of Thoracic Oncology. 14(10). S243–S244. 15 indexed citations

10.

Rugo, Hope S., Abhijit Barve, Cornelius F. Waller, et al.. (2016). Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab. Annals of Oncology. 27. vi555–vi555. 5 indexed citations

11.

Schüler, Martin, S-E. Al-Batran, Zanete Zvirbule, et al.. (2016). Final results of the FAST study, an international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Annals of Oncology. 27. vi208–vi208. 18 indexed citations

12.

Lordick, Florian, Martin Schüler, S-E. Al-Batran, et al.. (2016). 220O Claudin 18.2 - a novel treatment target in the multicenter, randomized, phase II FAST study, a trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without the anti-CLDN18.2 antibody IMAB362 as 1st line therapy in advanced gastric and gastroesophageal junction (GEJ) cancer. Annals of Oncology. 27. ix69–ix69. 2 indexed citations

13.

Bodoky, G., M. E. Scheulen, Fernando Rivera, et al.. (2015). Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS). Journal of Gastrointestinal Cancer. 46(2). 109–117. 15 indexed citations

14.

Novello, Silvia, Giorgio V. Scagliotti, Ihor Vynnychenko, et al.. (2014). Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Squamous Non–Small-Cell Lung Cancer: Results From the Randomized Controlled MONET1 Study. Journal of Thoracic Oncology. 9(8). 1154–1161. 14 indexed citations

15.

Waller, Cornelius F., Ihor Vynnychenko, Igor Bondarenko, et al.. (2014). An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 16(2). 92–99. 13 indexed citations

16.

Pirker, Robert, J. R. Pereira, Aleksandra Szczęsna, et al.. (2012). Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study. Lung Cancer. 77(2). 376–382. 5 indexed citations

17.

Ajani, Jaffer A., W. Rodriguez, G. Bodoky, et al.. (2010). Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial. Journal of Clinical Oncology. 28(9). 1547–1553. 425 indexed citations breakdown →

18.

Gatzemeier, U., Joachim von Pawel, Ihor Vynnychenko, et al.. (2010). First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. The Lancet Oncology. 12(1). 30–37. 88 indexed citations

19.

Pirker, Robert, Jose R. Pereira, Aleksandra Szczęsna, et al.. (2009). Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. The Lancet. 373(9674). 1525–1531. 1046 indexed citations breakdown →

20.

Vermorken, Jan B., Ricard Mesı́a, Fernando Rivera, et al.. (2008). Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer. New England Journal of Medicine. 359(11). 1116–1127. 2594 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact